Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties Academic Article uri icon

Overview

MeSH Major

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Antineoplastic Agents
  • Neoplasms

abstract

  • Recommended phase II doses are 500 mg/m(2) and 572 mg/m(2) IV once every 3 weeks for HP and MP patients, respectively. The absence of severe nonhematologic toxicities, the encouraging antitumor activity in HP patients, and the unique mechanism of antineoplastic activity of NSC 655649 warrant further clinical development.

publication date

  • June 2001

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2001.19.11.2937

PubMed ID

  • 11387367

Additional Document Info

start page

  • 2937

end page

  • 47

volume

  • 19

number

  • 11